Results 71 to 80 of about 843,336 (254)

Drug Coated Balloons Versus Drug‐Eluting Stents in Patients With De Novo Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with de novo coronary artery disease (CAD), percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation is the gold standard therapy. New evidence is available with drug coated balloons (DCB) angioplasty. The objective of this meta‐analysis was to compare the efficacy and safety of DCB angioplasty
Daniel O'Callaghan, Himanshu Rai, Daniele Giacoppo, J. J. Coughlan, Rory Durand, Valeria Paradies, Róisín Colleran, Gavin J. Blake, Fernando Alfonso, Robert A. Byrne   +9 more
wiley   +1 more source

Cytomegalovirus Infection and Coronary Restenosis [PDF]

Circulation, 1999
Current techniques of percutaneous transluminal coronary revascularization remain limited by the phenomenon of restenosis. The response of the vessel wall to the iatrogenic injury associated with coronary interventions is a complex and multifactorial process. Experimental and clinical studies suggest that a combination of different mechanisms, such as (
Michel E. Bertrand, Christophe Bauters
openaire   +2 more sources

The Predictive Value of Quantitative Flow Ratio and Its Derived Angiographic Microvascular Resistance for Restenosis Following Drug‐Coated Balloon Angioplasty

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Initially, drug‐coated balloon (DCB) angioplasty was primarily employed for in‐stent restenosis (ISR) treatment. Over time, its indications have broadened to include de novo small‐vessel lesions and bifurcation lesions. However, there is a lack of effective strategies to reduce restenosis rates post‐DCB angioplasty.
Chenhang Wang, Li Chen, Xiaoyong Xu
wiley   +1 more source

Restenosis risk factors after coronary stenting in metabolic syndrome patients

Кардиоваскулярная терапия и профилактика, 2007
This review is devoted to coronary restenosis after stent implantation in metabolic syndrome (MS) patients. It is known that some clinical factors increase restenosis risk, first of all, diabetes mellitus.
N. M. Danilov, T. T. Gorgadze, A. P. Savchenko, I. E. Chazova   +3 more
doaj  

Impact of Femoropopliteal Drug‐Coated Balloon Use on Clinical Outcomes in Patients With Chronic Limb‐Threatening Ischemia

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Drug‐coated balloons (DCBs) for femoropopliteal (FP) lesions have demonstrated superiority over standard percutaneous transluminal angioplasty (PTA) in maintaining vessel patency. However, data on whether the good durability of DCBs translates into improved wound outcome in chronic limb‐threatening ischemia (CLTI) patients are ...
Haruya Yamane, Yosuke Hata, Osamu Iida, Yasunori Ueda, Kuniyasu Ikeoka, Taku Toyoshima, Motoki Yasunaga, Hiroaki Nohara, Akito Kawamura, Sho Nakao, Yohei Sotomi, Yasushi Sakata   +11 more
wiley   +1 more source

Exercise stress testing before and after successful multivessel percutaneous transluminal coronary angioplasty

Brazilian Journal of Medical and Biological Research, 2006
Controversy exists regarding the diagnostic accuracy, optimal technique, and timing of exercise testing after percutaneous coronary intervention. The objectives of the present study were to analyze variables and the power of exercise testing to predict ...
W.A. Chalela, J.C. Kreling, A.M. Falcão, W. Hueb, P.J. Moffa, P.L.A. Pereyra, J.A.F. Ramires   +6 more
doaj   +1 more source

Cost‐Utility Analysis of Different Treatment Modalities in Patients Undergoing Percutaneous Coronary Intervention: Thai PCI Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cost‐utility analyses of percutaneous coronary interventions (PCIs) provide valuable insights into the economic value of these procedures. However, data is lacking, particularly in developing countries with limited resources. Aims This analysis aimed to compare the cost‐utility of different treatment modalities used for PCI patients
Oraluck Pattanaprateep, Thosaphol Limpijankit, Thunyarat Anothaisintawee, Sukanya Siriyotha, Nakarin Sansanayudh, Ammarin Thakkinstian   +5 more
wiley   +1 more source

Coronary In-Stent Restenosis: JACC State-of-the-Art Review.

Journal of the American College of Cardiology, 2022
G. Giustino, A. Colombo, A. Camaj, K. Yasumura, R. Mehran, G. Stone, A. Kini, Samin K. Sharma   +7 more
semanticscholar   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

Cell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang, Yue‐Yue Wang, Ri Wen, Tie‐Ning Zhang, Ni Yang   +4 more
wiley   +1 more source

Prediction of Coronary Artery Restenosis in Patients Undergoing Angioplasty

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2018
BACKGROUND AND OBJECTIVE: Coronary artery restenosis following angioplasty may lead to major unwanted cardiac events. This is one of the most important concerns of cardiologists.
F Ebrahimzadeh, M Salehi Veisi, E Hajizadeh, M Namdari   +3 more
doaj